Surgical intervention as a curative major for secondary hypertension
DOI:
https://doi.org/10.18203/2349-2902.isj20213151Keywords:
Functional paraganglioma, retroperitoneal paraganglioma, surgical management, Secondary hypertension, FDG-PETAbstract
Retroperitoneal functional paraganglioma is a rare type of neuroendocrine neoplasm which secrete excess catecholamines including epinephrine, norepinephrine, dopamine and their metabolites metanephrine, normetanephrine, 3-methoxytyramine respectively. Early diagnosis of functional paraganglioma is important because its removal is often curative. The extent of disease is evaluate using 2(18F)-fluoro-2 deoxy-D-glucose positron emission tomography (FDG-PET), where increased uptake of 18-FDG observed the mass. It is one of the rare curable causes of secondary hypertension. Here, we have presented the rare case of a young female who was recently diagnosed with hypertension and pain in abdomen, was later found to have functional paraganglioma.
References
Elder EE, Elder G, Larsson C. Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. J Surg Oncol. 2005;89(3):193.
Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23(34):8812-8.
Plouin PF, Gimenez-Roqueplo AP. Initial work-up and long term follow up in patients with phaeochromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metab. 2006;20:421-34.
Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366:665-75.
Hescot S, Curras-Freixes M, Deutschbein T. Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): a European network for the Study of Adrenal Tumors retrospective study. J Clin Endocrinol Metab. 2019; 104:2367-74.
Guerrero MA, Schreinemakers JM, Vriens MR. Clinical spectrum of pheochromocytoma . J Am Coll Surg. 2009;209:727-32.
Neumann HP, Bausch B, McWhinney SR. Germline mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346:1459-66.
Lenders JW, Duh QY, Eisenhofer G. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915-42.
Renard J, Clerici T, Licker M, Triponez F: Pheochromocytoma and abdominal paraganglioma. J Visc Surg. 2011;148:409-16.
Lenders JW, Pacak K, Walther MM. Biochemical diagnosis of pheochromocytoma: which test is best?. JAMA. 2002;287:1427-34.
Eisenhofer G, Bornstein SR, Brouwers FM. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer. 2004;11:423-36.
Ferreira MA, Vilaverde J. A genética dos feocromocitomas e paragangliomas. Rev Port Endocrinol Diabetes Metab. 2014;9:29-35.
Turchini J, Cheung VKY, Tischler AS, De Krijger RR, Gill AJ. Pathology and genetics of phaochromo-cytoma and paraganglioma. Histopathol. 2018;72:97-105.
Eisenhofer G, Tischler AS, de Krijger RR. Diagnostic tests and biomarkers for pheochromocytoma and extraadrenal paraganglioma: from routine laboratory methods to disease stratification. Endocr Pathol. 2012;23:4-14.
John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: can malignant potential be predicted? Urol. 1999;53:679-83.
